Physician profile
Ryan Lahey
NPI 1780242032
$3,886.84
in general payments reported to CMS, 2019-2025
33 companies · $772 in 2025
The $772 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $547 · 2022: $830 · 2023: $904 · 2024: $833 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $841.58 | 2021-2025 | |
| Pfizer INC. | $401.54 | 2021-2025 | |
| Novo Nordisk INC | $392.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $241.01 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $227.54 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Novartis Pharmaceuticals Corporation | $226.84 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $207.04 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $181.47 | 2021-2025 | Evenity, Prolia |
| Mylan Specialty L.P. | $157.00 | 2023-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $122.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.69 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $106.61 | 2022-2023 | Belsomra, Steglatro, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.46 | 2023-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.56 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $53.03 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $45.13 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $41.32 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $37.21 | 2021 | |
| Glaxosmithkline, LLC. | $35.15 | 2023-2024 | Bexsero, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $33.73 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.22 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $25.64 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.40 | 2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $18.99 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $18.08 | 2024 | Voquezna |
| Genentech USA, INC. | $17.78 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.37 | 2024 | Eliquis |
| Exact Sciences Corporation | $16.45 | 2025 | The Cologuard Plus Collection Kit |
| Viatris Specialty LLC | $16.34 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $16.02 | 2023 | Quviviq |
| Electromed, INC. | $15.02 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.